Prime time: First therapeutic clinical trial of C'Dots under

C’Dots, silica-encased nanoparticles developed in the lab of engineering professor Ulrich Wiesner, have just begun their first therapeutic human clinical trial. They’re being further developed by Elucida Oncology Inc., a company co-founded by Wiesner.

Related Keywords

New Jersey , United States , Monmouth Junction , Bard Hall , Kai Ma , Spencert Olin , Uli Wiesner , Melik Turker , Ulrich Wiesner , Paul Rudick , Tom Gardinier , Elucida Cdcs , Geno Germano , Fei Wu , Heaney Cornell University Dots , Tumor Group Expansion Cohort , Elucida Oncology Inc , Cornell Prime Dots , Elucida Oncology , New Jersey Based , Cornell University , Cornell Dots , Escalation Safety Study , Group Expansion Cohort ,